IBA Reports Full Year 2023 Results
GROUP REVENUES UP 18.7% WITH OTHER ACCELERATORS UP 51.1%
REBIT POSITIVE FOR FY23 WITH OTHER ACCELERATORS REBIT ALMOST QUADRUPLING
MEDIUM TERM GUIDANCE REITERATED
Louvain-la-Neuve, Belgium, 21st March 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces its consolidated results for the 2023 financial year.
Olivier Legrain, Chief Executive Officer of IBA, commented: “A strong second half performance has ensured we have delivered positive REBIT at the full year, with Group revenues in line with expectations.”
“Other Accelerators had a particularly strong year, with revenues growing more than 50% and a significant increase in REBIT driven by high order intake over the past few years and accelerated backlog conversion. Dosimetry performance was also strong, with growth in sales and REBIT, and the Services business continuing to perform well across the board. Meanwhile, Proton Therapy’s reduced performance reflects the significant investment into the future growth of the business alongside some delays in backlog conversion.”
“Looking ahead, IBA remains focused on keeping its supply chain moving and accelerating backlog conversion. Alongside this, investment is important for the business and will be executed with an agile and targeted approach.”
“As we continue to drive growth, I’m pleased to announce Henri de Romrée’s appointment as Deputy CEO, where he will focus on future opportunities and performance in the Other Accelerators business.”